» Articles » PMID: 37483500

RNA Atlas and Competing Endogenous RNA Regulation in Tissue-derived Exosomes from Luminal B and Triple-negative Breast Cancer Patients

Overview
Journal Front Oncol
Specialty Oncology
Date 2023 Jul 24
PMID 37483500
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Luminal B and triple-negative breast cancer (TNBC) are malignant subtypes of breast cancer (BC), which can be attributed to the multifaceted roles of tissue-derived exosomes (T-exos). Competing endogenous RNA (ceRNA) networks can regulate gene expression post-transcriptionally.

Methods: RNAs in T-exos from luminal B BC (=8) and TNBC (=8) patients were compared with those from persons with benign breast disease (=8). The differentially expressed (DE) mRNA, microRNA (miRNA), and long noncoding RNA (lncRNA) target genes were annotated using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) to reveal the relevant biological processes.The ceRNA networks were constructed to show distinct regulation, and the mRNAs involved were annotated. The miRNAs involved in the ceRNA networks were screened with the Kaplan-Meier Plotter database to identify dysregulated ceRNAs with prognostic power.

Results: In total, 802 DE mRNAs, 441 DE lncRNAs, and 104 DE miRNAs were identified in luminal B BC T-exos, while 1699 DE mRNAs, 590 DE lncRNAs, and 277 DE miRNAs were identified in TNBC T-exos. Gene annotation revealed that the RAS-MAPK pathway was the primary biological process in luminal B BC T-exos, while endocrine system development and growth were the main processes in TNBC T-exos. Survival analysis established seven survival-related lncRNA/miRNA/mRNA regulations in luminal B BC T-exos, and nineteen survival-related lncRNA/miRNA/mRNA regulations in TNBC T-exos.

Conclusion: In addition to survival-related ceRNA regulations, ceRNA regulation of RAS-MAPK in luminal B and endocrine system development and growth regulation in TNBC might contribute to the tumorigenesis of BC.

Citing Articles

Development of a prognostic model based on the ceRNA network in Triple-Negative Breast cancer.

Zhu Y, Wang J, Xu B PeerJ. 2025; 13:e19063.

PMID: 40034665 PMC: 11874946. DOI: 10.7717/peerj.19063.


LUCAT1-Mediated Competing Endogenous RNA (ceRNA) Network in Triple-Negative Breast Cancer.

Verma D, Siddharth S, Yende A, Wu Q, Sharma D Cells. 2024; 13(22).

PMID: 39594666 PMC: 11593075. DOI: 10.3390/cells13221918.


lncRNA PAARH impacts liver cancer cell proliferation by engaging miR‑6512‑3p to target LASP1.

Wei Q, Liu G, Huang Z, Nian J, Huang L, Huang Y Oncol Lett. 2024; 28(1):306.

PMID: 38774456 PMC: 11106750. DOI: 10.3892/ol.2024.14439.

References
1.
Bie N, Yong T, Wei Z, Gan L, Yang X . Extracellular vesicles for improved tumor accumulation and penetration. Adv Drug Deliv Rev. 2022; 188:114450. DOI: 10.1016/j.addr.2022.114450. View

2.
Li P, Liu C, Qian L, Zheng Z, Li C, Lian Z . miR-10396b-3p inhibits mechanical stress-induced ligamentum flavum hypertrophy by targeting IL-11. FASEB J. 2021; 35(6):e21676. DOI: 10.1096/fj.202100169RR. View

3.
Zhou X, Liu J, Wang W . Construction and investigation of breast-cancer-specific ceRNA network based on the mRNA and miRNA expression data. IET Syst Biol. 2014; 8(3):96-103. PMC: 8687191. DOI: 10.1049/iet-syb.2013.0025. View

4.
Lanczky A, Nagy A, Bottai G, Munkacsy G, Szabo A, Santarpia L . miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016; 160(3):439-446. DOI: 10.1007/s10549-016-4013-7. View

5.
Yin L, Duan J, Bian X, Yu S . Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020; 22(1):61. PMC: 7285581. DOI: 10.1186/s13058-020-01296-5. View